TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9197957

Group type: EXPERIMENTAL
Intervention: Detergent solutions at 37 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detergent solutions at 40 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detergent with higher anionic content at both temperatures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detergent with lower anionic content at both temperatures
Number of subjects: 0
Study: 1609940

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intravenous pethidine
Number of subjects: 71
Study: 4029895

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Domperidone (equivalent dose to metoclopramide)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg) with spironolactone (300 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Domperidone (equivalent dose to metoclopramide) with spironolactone (300 mg/day)
Number of subjects: 35
Study: 29676944

Group type: EXPERIMENTAL
Intervention: CTS5 (Clinical Treatment Score post-5 years)
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: CTS5 risk stratification
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Final CTS5 algorithm
Number of subjects: 11846
Study: 27749954

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) plus 5 doses of 100 mL decaffeinated coffee (total 500 mg caffeine)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (lactose capsules) plus 5 doses of 100 mL decaffeinated coffee
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion with higher plasma caffeine concentration
Number of subjects: 51
Study: 24002341

Group type: EXPERIMENTAL
Intervention: Speed Treadmill Training (TT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mixed Treadmill Training (TT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 23131971

Group type: EXPERIMENTAL
Intervention: Health and wellness therapy group (n = 37)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control (n = 37)
Number of subjects: 74
Study: 19944581

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol xinafoate (FSC) 100/50 microg twice daily
Number of subjects: 526

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice daily
Number of subjects: 526
Study: 18388880

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Reinforcement ($12/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 140
Study: 15736893

Group type: EXPERIMENTAL
Intervention: Florida Probe (FP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual Probe (MP)
Number of subjects: 20
Study: 11448906

Group type: EXPERIMENTAL
Intervention: Suramin treatment in patients with HRPC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma VEGF levels
Number of subjects: 0
Study: 9649013

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day plus Ursodeoxycholic acid 600 mg/day (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid 600 mg/day (group 2)
Number of subjects: 50
Study: 8596756

Group type: EXPERIMENTAL
Intervention: Uraemic group (HD treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 2570000

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine at 1 h before challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine at 2 h before challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine at 1 and 2 h before challenge
Number of subjects: 10
Study: 1192697

Group type: EXPERIMENTAL
Intervention: Dipeptide glycyl‐L‐alanine and its constituent amino acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium chloride solution (150 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dipeptide concentrations
Number of subjects: 0
Study: 30815700

Group type: EXPERIMENTAL
Intervention: Maternal environmental exposures (specific exposures not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical model for estimating maternal genotypes' effect on offspring outcomes
Number of subjects: 0
Study: 28367694

Group type: EXPERIMENTAL
Intervention: MTPJ arthrodesis
Number of subjects: 52

Group type: COMPARATOR
Intervention: MTPJ arthroplasty
Number of subjects: 52
Study: 27465676

Group type: EXPERIMENTAL
Intervention: Manual therapy added to standard treatment (repositioning and an orthotic helmet)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment (repositioning and an orthotic helmet)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Manual therapy added to standard treatment
Number of subjects: 46
Study: 24854418

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 265
Study: 22055763

Group type: EXPERIMENTAL
Intervention: Dose-dense weekly paclitaxel (ddT) plus carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Every-3-week paclitaxel (q3T) plus carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including treatment administration (ddT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy including treatment administration (q3T)
Number of subjects: 0
Study: 19578177

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls without heart failure
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AVD shortening in CRT patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AVD prolongation in CRT patients
Number of subjects: 36
Study: 17452935

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 2640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2640
Study: 14693625

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (0.2 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 12563568

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9823811

Group type: EXPERIMENTAL
Intervention: Postoperative drainage
Number of subjects: 40

Group type: COMPARATOR
Intervention: No postoperative drainage
Number of subjects: 40
Study: 7859550

Group type: EXPERIMENTAL
Intervention: Allocation of money to characters described as friends
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation of money to characters described as strangers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allocations and fairness ratings by kindergartners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rationales for allocation judgments
Number of subjects: 0
Study: 2569730

Group type: EXPERIMENTAL
Intervention: Broxaterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 10
Study: 1067277

Group type: EXPERIMENTAL
Intervention: multitufted nylon brush
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: wooden toothpick
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: unwaxed dental floss
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: combined cleaning exercise with all three instruments
Number of subjects: 21

Group type: COMPARATOR
Intervention: none
Number of subjects: 21
Study: 31081593

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors or SGLT-1/2 inhibitors as adjunct to insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: SGLT-2 inhibitors or SGLT-1/2 inhibitors
Number of subjects: 0
Study: 28566897

Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (LFD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal diet (ND)
Number of subjects: 89
Study: 25819949

Group type: EXPERIMENTAL
Intervention: Responsive neurostimulation
Number of subjects: 191

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 191
Study: 23347236

Group type: EXPERIMENTAL
Intervention: Early subjective response (SR)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Acquired tolerance
Number of subjects: 113
Study: 21091369

Group type: COMPARATOR
Intervention: Intravenous ketorolac plus iliac crest normal saline infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac plus iliac crest bupivacaine infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Iliac crest bupivacaine infusion alone
Number of subjects: 54
Study: 19107130

Group type: EXPERIMENTAL
Intervention: Intervention (17-item patient-completed continuity assessment and feedback to clinical nurse specialists)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intervention (feedback from continuity assessment to clinicians)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (not explicitly defined in the abstract)
Number of subjects: 61
Study: 17227568

Group type: EXPERIMENTAL
Intervention: HBV vaccination pretransplant and lamivudine posttransplant for anti‐HBc(+) grafts for about 2 years
Number of subjects: 60
Study: 14706436

Group type: EXPERIMENTAL
Intervention: 100g amino acid drink with tryptophan
Number of subjects: 14

Group type: COMPARATOR
Intervention: 100g amino acid drink without tryptophan
Number of subjects: 14
Study: 11597291

Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d, n = 2837)
Number of subjects: 5720

Group type: COMPARATOR
Intervention: Placebo (n = 2883)
Number of subjects: 5720

Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d)
Number of subjects: 5720
Study: 9439401

Group type: EXPERIMENTAL
Intervention: KTP laser bladder neck incision (BNI) with Nd:YAG endoscopic ablation (ELAP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nd:YAG endoscopic ablation (ELAP) alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (KTP BNI + ELAP and ELAP alone)
Number of subjects: 88
Study: 1790748

Group type: EXPERIMENTAL
Intervention: Timolol 0.1% eye drops, applied twice daily for one week before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops, applied twice daily for one week before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo eye drops, applied twice daily for one week before surgery
Number of subjects: 60
Study: 6803819

Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg/day in the first week, 1 g/day in the second week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30037560

Group type: EXPERIMENTAL
Intervention: Extended dwell catheter (EDC), 6 cm 3 French (19.5 gauge) Access Scientific POWERWAND™
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard long IV catheter, 4.78 cm 20 gauge Becton Dickinson (BD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Extended dwell catheter (EDC)
Number of subjects: 120
Study: 27887881

Group type: EXPERIMENTAL
Intervention: Sedation with daily wake up
Number of subjects: 36

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 36
Study: 25171906

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in participants with BMI ≥ 30 kg/m²
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Storage score of 4 or greater in participants with BMI ≥ 30 kg/m²
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in participants with abdominal obesity
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Storage score of 4 or greater in participants with abdominal obesity
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in men and women younger than 50 years
Number of subjects: 4144
Study: 23621572

Group type: EXPERIMENTAL
Intervention: Triple-layered covered SEMS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 62
Study: 21495914

Group type: EXPERIMENTAL
Intervention: Neater Uni‐Wheelchair (NUW) kit attachment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Action 3 wheelchair
Number of subjects: 20
Study: 20973685

Group type: EXPERIMENTAL
Intervention: Bivalirudin 2 mg/hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heparin 400 units/hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 10
Study: 18621591

Group type: EXPERIMENTAL
Intervention: 100mg trazodone tablet formulation
Number of subjects: 36
Study: 15928463

Group type: EXPERIMENTAL
Intervention: 3 minutes of chest compressions prior to defibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate defibrillation
Number of subjects: 0
Study: 12119515

Group type: EXPERIMENTAL
Intervention: Pyloric drainage (pyloroplasty or pyloromyotomy)
Number of subjects: 553

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 553
Study: 10347132

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b, 3 million units three times per week for 48 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: No antiviral therapy (Control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 99
Study: 8817829

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (Engerix‐B, 10 micrograms dose‐1)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) conjugate vaccine
Number of subjects: 5000
Study: 1307052

Group type: EXPERIMENTAL
Intervention: Alpinia speciosa
Number of subjects: 10
Study: 4054192

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31005923

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64
Study: 28843031

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) prescribed to individuals scoring over 13 points on FINDRISC; 2.8% of population survey and 75.4% of opportunistic survey participants took the OGTT.
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: HbA1c levels measured in participants with normal glucose tolerance, prediabetes, and T2D.
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Assessment of lipid profiles in participants with prediabetes and T2D.
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Evaluation of insulin resistance in individuals with prediabetes.
Number of subjects: 3759
Study: 26823294

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 81

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 81
Study: 24952057

Group type: EXPERIMENTAL
Intervention: FemoSeal VCD
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: EXOSEAL VCD
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 4500
Study: 21848980

Group type: EXPERIMENTAL
Intervention: Aluminium chloride 12.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aluminium chloride 30%
Number of subjects: 20
Study: 20071440

Group type: EXPERIMENTAL
Intervention: HIV disclosure in Northern Thailand
Number of subjects: 410

Group type: COMPARATOR
Intervention: HIV disclosure in Northeastern Thailand
Number of subjects: 410
Study: 17584825

Group type: EXPERIMENTAL
Intervention: Paclitaxel with 5-fluorouracil
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Paclitaxel with S-1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sequential regimen (specifics not provided)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination regimen (specifics not provided)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 16132888

Group type: EXPERIMENTAL
Intervention: Ventilation with lower tidal volume (V(T) of 6 ml/kg ideal body weight)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ventilation with higher tidal volume (V(T) of 12 ml/kg ideal body weight)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lower tidal volume ventilation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Higher tidal volume ventilation
Number of subjects: 44
Study: 12034024

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (3 x 10(6) IU) three times weekly for 8-16 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (1.5-6 x 10(6) IU) three times weekly for 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a re-administration after discontinuation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a treatment
Number of subjects: 44
Study: 10462652

Group type: EXPERIMENTAL
Intervention: Needle-knife fistulotomy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Needle-knife precut papillotomy
Number of subjects: 103
Study: 8703666

Group type: EXPERIMENTAL
Intervention: ANP (10 pmol kg‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BNP (10 pmol kg‐1 min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 8
Study: 2147175

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) for 36 weeks followed by a placebo period of 4 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (9 g/day) for 36 weeks with a subsequent period of 4 weeks in which fish oil placebo was given
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) for 12 weeks, propranolol plus fish oil capsules (9 g/day) for 12 weeks, propranolol plus fish oil placebo for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 47
Study: 6972101

Group type: EXPERIMENTAL
Intervention: Antrafenine 450 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Antrafenine 900 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aspirin 1.8 g/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31046719

Group type: EXPERIMENTAL
Intervention: Endurance plus balance training (twice weekly over 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endurance training (twice weekly over 12 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endurance plus balance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 50
Study: 28874595

Group type: EXPERIMENTAL
Intervention: Usual funds plus additional funds (ranging from $6,750 to $234,000 AUD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual CTMS funds
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intervention sites compared to control sites
Number of subjects: 34
Study: 25979300

Group type: EXPERIMENTAL
Intervention: RIFL video laryngoscope
Number of subjects: 132

Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 132
Study: 23644816

Group type: EXPERIMENTAL
Intervention: Telephone based cognitive behavioral therapy (T-CBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Face-to-face therapy (f2f)
Number of subjects: 34
Study: 22852117

Group type: EXPERIMENTAL
Intervention: Curcumin 1000 mg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19674861

Group type: EXPERIMENTAL
Intervention: Emotional intelligence developmental training workshops
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study: 15923279

Group type: EXPERIMENTAL
Intervention: Carbon particles (50 microg/m3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphur dioxide (200 ppb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon particles and SO2
Number of subjects: 0
Study: 15526058

Group type: EXPERIMENTAL
Intervention: DNA ME-TRAP followed by MVA ME-TRAP
Number of subjects: 372

Group type: COMPARATOR
Intervention: rabies vaccine (control)
Number of subjects: 372
Study: 11251139

Group type: EXPERIMENTAL
Intervention: Lidocaine (2%, 0.5 mL) mixed with radiopaque fluid (0.25 mL) injected after verifying target location using sensory and motor electrostimulation.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard dermatomal map
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adapted dermatomal map
Number of subjects: 29
Study: 9684395

Group type: EXPERIMENTAL
Intervention: Full intervention (referral to treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no HIS program)
Number of subjects: 0
Study: 8162672

Group type: EXPERIMENTAL
Intervention: bretazenil
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 3369999

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31944812

Group type: EXPERIMENTAL
Intervention: Downward temporal comparisons
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Downward social comparisons
Number of subjects: 583

Group type: COMPARATOR
Intervention: Upward social comparisons
Number of subjects: 583

Group type: COMPARATOR
Intervention: Upward temporal comparisons
Number of subjects: 583

Group type: COMPARATOR
Intervention: No comparison
Number of subjects: 583
Study: 29987027

Group type: EXPERIMENTAL
Intervention: Circadian misalignment protocol (3.5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control protocol (3 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Circadian misalignment protocol
Number of subjects: 14
Study: 27793135

Group type: EXPERIMENTAL
Intervention: Cement augmented locking plate Philos™
Number of subjects: 40

Group type: COMPARATOR
Intervention: Proximal humerus nail MultiLoc®
Number of subjects: 40
Study: 25703058

Group type: EXPERIMENTAL
Intervention: Gel cuff applied to the most severely affected lower leg skin for 30 min daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control cuff
Number of subjects: 0
Study: 23327604

Group type: EXPERIMENTAL
Intervention: EMD + NBM + PRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: EMD + NBM
Number of subjects: 24